MTIP is the largest Pan-European growth equity investor purely focused on the healthtech sector, supporting companies that revolutionize global healthcare whilst generating top quartile returns to their investors. They invest in the most innovative healthtech companies that bring efficiency on healthcare accessibility, affordability, availability as well as quality. MTIP has a proven ability to invest across Europe with investments so far in 11 different European jurisdictions as well as internationally (e.g. USA, Israel), with a portfolio that includes Oviva, Trialbee and Intelligencia. MTIP’s purpose is to empower innovation that improves lives by accelerating the adoption of digital technologies in healthcare. They do this across digital health products, tech-enabled healthcare services as well as connected medical devices. As a leading impact investor, MTIP actively engages with their portfolio companies on ESG topics, and believes social responsibility is critical for long-term and sustainable value creation. Thus, the Swiss-based growth equity firm is proud to be SFDR Art.9 compliant as of MTIP Fund II onwards characterized as one of the first “dark green“ funds with their products targeting sustainable investments.
Our Members
Membership Options
Find out More
To find out more about EHIA, download our credentials deck which provides some background on the Association, our current members, and member benefits.
To arrange an exploratory call please contact our Executive Director Sarah Ward.
European Healthcare Investor Association is a not-for-profit organisation answerable to its members in the annual general meeting. Our members are investors, current and former board members and senior managers of portfolio companies and advisors to the healthcare private equity community.
Investor Members
Investment funds active in healthcare comprising private equity, infrastructure, sovereign funds, foundations, real estate investors and family offices that meet the following criteria:
- more than €200m AUM
- two or more current or former healthcare portfolio companies or assets
- two or more nominated healthcare-focused investment professionals
Strategic Partners
Advisors active in the healthcare sector who support the Association with content and events
Associate Members
There are two tiers of Associate Membership available. One is for Corporate entities within the healthcare sector; the other is for Advisors active in the healthcare sector that are not Strategic Partners.
Individual Members
Individual membership is specifically reserved for current or former CEOs, Chairs, or Non-Executive Directors of portfolio companies of investors who satisfy the membership criteria (see above). This is designed to facilitate interactions between investors and leading executives within the sector. Applicants must hold or have held a C-suite position in a portfolio company of an investor who meets our membership criteria. It is not a requirement for the investor to be a member of EHIA, although they may be.
Investor Members
Strategic Partners
Corporate Associate Members
Advisory Associate Members
Individual Members
Membership Benefits
Events and Networking
Invitations to exclusive dinners, breakfast seminars, networking drinks and report launches including:
- Investors in Healthcare Gala Dinner in London (during Jefferies)
- Women in Healthcare Investing networking events
- Investors in Healthcare drinks in San Francisco (during JP Morgan)
- Healthcare Investing in Germany Networking Dinner in Dusseldorf (during Medica)
- European Healthcare & Life Sciences Investor Symposium in Frankfurt, Paris and London
- Healthcare Investing Networking Dinner during CPHI
Discounts to industry events including:
- Complimentary tickets for Investor Members to McDermott’s HPE Europe Conference London (value £695 per ticket)
- Discount to Investors in Healthcare Private Capital Conference London
- Discount to Investors in Healthcare Real Assets Conference London
- Discount to SuperReturn International Berlin (£1,200 per ticket)
- Discount to HLTH Europe Amsterdam
Opportunity to partner with EHIA on events with marketing support provided
Content and Community
Access to exclusive Member-only Webinars and On-Demand content including:
- Investing in Healthcare Insights with L.E.K. Consulting
- Legal Insight with McDermott Will & Schulte
- Meet Your Members
Monthly newsletter containing:
- Member-only content
- Industry event calendar
- Latest transactions, with advisors and valuations
- Sector appointments
Complimentary Enterprise subscription to Investors in Healthcare, providing sector focussed news, data and analysis (value £1,495 p.a.)
Industry engagement, sector news through web site, e newsletters and LinkedIn: 15,000+ followers
Promotion of your brand and investment activities to the EHIA community
Membership includes access for an extensive number of team members per organisation (discretionary)
Investor Members
Apposite Capital solely focuses on healthcare. It works closely with management teams, providing operational support and strategic guidance as much as capital to together build market-leading companies. It invests in high potential commercial-stage companies across Europe, with each investment tailored to each company’s needs and with a view to all types of financing structures (minority, growth, buyout, buyin, etc). Apposite typically seeks to invest £10-20 million over the life of each investment but an initial investment can be £5 million or less.
Astorg is a leading European private equity firm with over €23bn of assets under management, investing exclusively in B2B international leaders across 3 sectors: Healthcare, Technology, and Business Services. With deep sector expertise and a creative, long-term approach, Astorg backs and accelerate the growth of premium companies with strong differentiation, pricing power, and international scale. Astorg’s Healthcare practice is one of the firm’s deepest areas of expertise, focused exclusively on a narrow set of sub-sectors: pharmaceutical services and technology, MedTech and MedTech services, life science tools, and diagnostics. Within Healthcare, Astorg invests behind two core themes: enabling pharma innovation and improving efficiency across the pharmaceutical and MedTech value chain. Astorg’s disciplined model and strong focus has made it one of Europe’s most active Healthcare investors. The firm continues to leverage its long-term vision and creative dealmaking to build businesses that shape the future of healthcare innovation and efficiency.
Bridgepoint is one of the world’s leading quoted private asset growth investors, specialising in private equity, infrastructure and private credit. With €67bn of assets under management and a strong local presence in Europe, North America and Asia. Bridgepoint combines global scale with local market insight and sector expertise, consistently delivering strong returns through cycles. Bridgepoint’s Healthcare sector team focus investments on businesses leading in their niche, with strong intellectual property, and that benefit from long-term thematic / macro drivers, often with potential for accelerated growth through internationalisation or M&A.
capiton AG is an owner-managed private equity investor with a current fund volume of €1.3bn under management and a strong track record of over 20 years of investing in profitable companies in the DACH region. Currently investing out of their sixth fund, capiton’s key sectors are pharmaceuticals, medical and industrial technology and responsible consumption.
Founded in 1934, Charterhouse is one of the longest-established private equity firms operating in Europe and a pioneer of the European LBO market. The firm has €6bn in AUM today and targets mid-market transactions with an enterprise value of between €150 million and €1.5 billion. Headquartered in London, Charterhouse is 100% employee-owned and has a team representing 19 nationalities. The firm follows a conviction-led, pan-European investment strategy into two core sectors: Healthcare and Services (including Education), backing founders and management teams and helping to drive growth through buy-and-build, internationalisation and professionalisation.
Civitas invests principally in healthcare real estate through lasting partnerships with operating tenants. With £3.5 billion assets under advisory, their investment strategies target long-term predictable income streams whilst generating positive, measurable social and environmental impact. Civitas are the largest landlord of specialist care properties in the UK with a portfolio spanning supported living, adult’s residential care, mental health services, children’s homes, and special schools. Most recently they have started investing into UK senior living and have expanded geographically to include Continental Europe. Civitas can invest in deals ranging from £5 million to £1 billion plus. To date they have invested through a combination of sale and leasebacks (for established services) and forward funding (for new developments). They also partner with private equity investors and operators seeking an efficient source of capital for M&A or to reduce debt leverage.
Established in 1981, CVC is a world leader in private equity and credit with $109.1 billion of assets under management, $160.3 billion of funds committed and a global network of 23 local offices: 15 across Europe and the Americas and eight in the Asia Pacific region. CVC is majority owned by its employees and led by its Managing Partners. CVC’s private equity platform manages $82 billion of assets and comprises four strategies: Europe/Americas; Asia; Strategic Opportunities; and Growth Partners, each of which benefits from CVC’s global platform. CVC’s ability to bring to bear the full extent of its global resources on any situation gives it a competitive advantage when sourcing new investment opportunities and when creating value during CVC’s ownership period.
ECI Partners is a leading private equity investor, focussed on offering collaborative support to management teams. With funds under management exceeding £2 billion, ECI invests in growth businesses, targeting companies valued up to £300 million. ECI’s collaborative approach has been the foundation of their exceptional results for over 45 years.
Previous successful HealthTech investments for ECI include Clinisys, Harmoni and Ascribe, and most recently 4ways (delivering 2.7x return on exit)
Eurazeo is a leading global investment group, with a diversified portfolio of €32.5 billion in assets under management, including €23.4 billion from third parties, invested in over 530 companies. With its considerable Private Equity, real estate, private debt and fund of funds expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 360 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.
Five Arrows is the alternative assets arm of Rothschild & Co and has more than €23 billion AuM with offices in Paris, London, New York, Los Angeles, San Francisco and Luxembourg. With over €9 billion of assets under management, the corporate private equity business of Five Arrows is focused on investing in companies with highly defensible market positions; strong management teams; business models with high visibility of organic unit volume growth and strong unit economics; and multiple operational levers that can be used to unlock latent value. Sectors are limited to data and software, technology‑enabled business services and healthcare.
Gilde Healthcare is a specialized European healthcare investment firm. It manages €2.6 billion across its dedicated healthcare private equity and venture capital & growth funds. Gilde Healthcare has a track-record of superior returns spanning over 20 years. The firm employs 30 dedicated healthcare investment professionals with deep sector expertise across its offices in The Netherlands, Germany, and the US. The latest 500M Gilde Healthcare Private Equity Fund IV targets lower mid-market companies in North-Western Europe. Its portfolio includes successful investments in CRO/CDMO, Pharma, MedTech, Health IT and Care Providers. Recent PE investments include SDS Swiss Dental Solutions AG, a leading Swiss provider of ceramic dental implants, Essange Reagents, a Dutch developer and manufacturer of highly specialized IVD reagents, DETAX GmbH, a German producer of high end medical materials, Diener and Koscher&Wuertz, together forming a German CDMO group for precision surgical instruments, Ace Pharmaceuticals, a leading Dutch specialty pharma company focusing on medical need product and KLIFO, a Danish drug development consultancy. Through its investments, Gilde Healthcare actively contributes to its investment philosophy that enables Better Care at Lower Cost.
Gimv is a European investment company listed on Euronext Brussels with €2 billion AUM. With 60 portfolio companies currently under management, Gimv’s five platforms are: Consumer, Healthcare, Life Sciences, Smart Industries and Sustainable Cities. Through its Healthcare platform, Gimv is investing in care & patient providers, in leading B2B service & software companies in the healthcare sector and in healthcare products. The Life Sciences platform focuses on venture capital investments in pre-revenue R&D-driven companies that positively impact human health.
Goodgrower is a specialised healthcare investment firm with over €1bn of assets under management. Since 2007, they have backed numerous healthcare businesses and entrepreneurs worldwide. Their international team makes growth and buyout investments in healthcare businesses in Europe and the US, with tickets up to €30m. Goodgrower invests in subsectors like outsourced pharma services, medtech, healthcare IT, diagnostics, outpatient care/specialty clinics, consumer healthcare and animal health. They do not invest in pharma and biotech. Their portfolio also includes the second largest private hospital group in Spain (Vithas). Goodgrower is backed and entirely funded by the Gallardo Family, founders and main shareholders of pharmaceutical company Almirall.
With over seventy years of stock exchange listing, Groupe Bruxelles Lambert (“GBL”) is an established investment holding company with a net asset value of approximately €16 billion. As a leading and active investor in Europe, GBL focuses on long-term value creation with the support of a stable family shareholder base. GBL aims to grow its diversified high-quality portfolio of listed, private and alternative investments and is focused on delivering meaningful growth by providing attractive returns to its shareholders. This is done through a combination of growth in its net asset value per share, a sustainable dividend and share buybacks. GBL is listed on Euronext Brussels and is a leading company in the BEL20 index.
H.I.G. Capital is a leading global alternative investment firm with $43 billion of equity capital under management with a focus on the small cap and mid cap segments of the market. H.I.G. Private Equity funds focus on leveraged buyouts and recapitalizations, including corporate divestitures and take-private transactions, typically in partnership with existing management in small and mid-sized companies that can benefit from H.I.G.’s in-house operating professionals and expertise. H.I.G. has invested in and managed more than 300 companies worldwide since its founding in 1993, with combined sales in excess of $30 billion. H.I.G. has offices in the U.S. and affiliate offices in Europe and Latin America.
IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK. Since 1989, IK has raised more than €19 billion of capital and invested in 199 European companies. IK supports companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects.
For more than three decades, IK has been supporting high-quality businesses in the #Healthcare sector, unlocking value through a range of initiatives in the areas of scalability, technological innovation, procurement and operational consolidation. To date, IK has invested in 29 companies across its subsectors (MedTech, Pharma Services and Healthcare Services) and deployed €2.6 billion of capital. Recent investments include Eurobio Scientific, Defibrion, BIOBank S.A., Medica Group and Unither Pharmaceuticals.
For more information, please visit
https://ikpartners.com/sector/healthcare/
Established in 1997, Invision AG is one of the most experienced owner-managed private equity investors headquartered in the DACH region. The firm manages more than EUR 1bn AuM and recently raised its seventh fund. For more than two decades, Invision has a track record of supporting high-quality businesses jointly with the founding families, entrepreneurs, and managers. While Invision is investing across a variety of sectors, healthcare has always been one of the core sectors and still is to date. The current healthcare portfolio consists of Lipclinic, Vista Alpina, NonStop Gym and Careanesth.
Jacobs Capital is a mid-market private equity investment firm funded by family capital. With offices in London, Luxembourg, and Zurich the firm makes €100-300 million equity investments as a majority shareholder in companies within business services, consumer, education, and healthcare across Europe. Jacobs Capital has an entrepreneurial approach, a flexible and nimble decision making structure and the flexibility to hold and grow businesses over longer periods than traditional private equity firms.
Keensight Capital (“Keensight”), one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. With over 25 years of experience and more than €8bn of assets under management, Keensight Capital’s team of seasoned professionals leverages their differentiated private equity experience to invest in profitably growing companies generating revenues in the range of €10 million to €400 million. Drawing on its expertise in the Technology and Healthcare sectors, Keensight identifies the best investment opportunities in Europe and works closely with the management teams providing capital, strategic guidance and operational support. Keensight operates in more than 90 countries across the globe with a presence in Paris, London, Boston, and Singapore.
Founded in 2013, LetterOne is a partnership of successful entrepreneurs, CEOs and international business leaders with an evergreen capital structure, capable of underwriting longer investment horizons and ambitious growth plans. With over $20bn Aum, the firm has a global mandate of investing in sectors fundamental to society’s sustainable prosperity: Energy, Technology, Health and Retail. L1 is not answerable to the demands and short-termism of external capital. It can dedicate the time it takes to build industry leaders, invest throughout the economic cycle, and tailor its approach to each opportunity – from minority stakes to majority control, from start-up companies
Livingbridge is a mid-market private equity firm with offices in the UK, the US and Australia, which invests in fast-growing companies valued up to £300m. The team has backed growing companies for more than 20 years and achieved success with over 160 investments, turning many into household names, both in the UK and abroad. Livingbridge applies the entrepreneurial mindset that supports its own business to understand the people behind growing companies in four fast-moving markets: Services, Technology, Consumer and Healthcare & Education.
As a leading European private equity investor, Nordic Capital helps to grow stronger sustainable companies. With deep sector knowledge and long experience, they drive transformative growth. Nordic Capital is an active, engaged owner that works in close collaboration with portfolio companies, accelerating growth and often identifying truly transformative angles. Their goal is to use operational experience, capital and business acumen to create strong, sustainable businesses that will thrive in the long term.
Nordstjernan is a family-controlled and foundation-owned European owner and investor founded in 1890 and headquartered in Stockholm. Nordstjernan’s purpose is to safeguard the longevity of their foundation owners and be a custodian of over 130 years of industrial heritage. Nordstjernan seeks to generate strong risk-adjusted returns over cycles as active and responsible owners, managing a portfolio of close to EUR 4 billion through direct majority and minority holdings in public and private companies – with a deep expertise in sectors such as Healthcare, Industrials, Business Services and Construction. In addition to investing from their own balance sheet, Nordstjernan also invests in traditional private equity in partnership with Sigla (www.sigla-capital.com) and in credit through Nordstjernan Kredit. www.nordstjernan.se
Nordstjernan’s current healthcare investments include Etac (a world-leading developer and supplier of assistive devices), Aidian (a leader in European point-of-care diagnostics) and Prima Vård (one of the largest primary care platforms in the Nordics).
Novo Holdings A/S, a private limited liability company fully owned by the Novo Nordisk Foundation, is the holding company in the Novo Group, and responsible for managing the Foundation’s assets.
Besides being the major shareholder in the Novo Group companies Novo Nordisk A/S, Novozymes A/S and NNIT A/S, Novo Holdings provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science, as well as manages a broad portfolio of financial assets.
PAI Partners is a pre-eminent private equity firm investing in market-leading companies across Europe and North America. It manages c. €26 billion of dedicated buyout funds and, since 1994, has completed over 100 investments in 12 countries, representing over €70 billion in transaction value. For more than two decades, PAI has supported a high-quality portfolio of healthcare businesses, leading consolidation of fragmented markets and accelerating organic growth by leveraging its Consumer playbook into Healthcare and capitalising on the rise of outsourcing. The PAI team has successfully completed 11 deals across multiple healthcare sub-sectors: pharma, healthcare services, medtech and diagnostics. This includes Atos Medical, Cerba Healthcare, DomusVi, ELITech, Theramex and Veonet.
Partners Group is a leading global private markets firm. Since its establishment in 1996, the firm has invested USD 210 billion in private equity, private real estate, private debt, and private infrastructure on behalf of its clients worldwide. Partners Group aims to generate superior returns by capitalizing on thematic growth trends, transforming attractive businesses and assets into market leaders. The firm is committed to responsible investing, striving to create sustainable returns with a lasting, positive impact on all its stakeholders. With USD 147 billion in assets under management, Partners Group offers an innovative range of tailor-made client solutions to institutional investors, sovereign wealth funds, family offices and private individuals globally.
The Riverside Company is a global private investment firm focused on driving growth for companies at the smaller end of the middle market in Europe, North America and Australia. With approximately $13 billion in assets under management, Riverside has completed more than 1,000 investments since its founding in 1988. Healthcare investing is one of Riverside’s most active specializations, with more than 200 deals completed in the space. The firm’s current portfolio, inclusive of add-ons, features more than 65 healthcare company investments. In Europe, the latest Riverside Europe Fund targets control buyouts of companies with up to €30 million EBITDA. Visit https://www.riversidecompany.com/industries/healthcare/ to learn more about Riverside’s Healthcare specialization.
.
Triton is an investment firm that invests primarily in German-speaking and the Nordic countries, the Benelux region, France, Italy, Spain and the United Kingdom in the industrials, business service, consumer and health sectors. They focus on companies with the potential to create sustainable, long-term value through changing economic cycles and we work closely with management to achieve that. Our investments are supported by three core principles: Thoughtful investing; Consistent strategy and Responsibility.
Verlinvest is an international, family-backed investment company focused on backing businesses that are driving consumer revolutions. Established in 1995, with offices in Europe, the US and Asia, Verlinvest has over €2bn in assets under management and focuses on the FMCG, health, consumer technology and lifestyle categories, investing across three strategies: Platform, Growth & Venture. In healthcare, Verlinvest looks for companies that put patient-consumers at the heart of everything they do. In Europe, this typically means investing €40m to €250m for control or co-control positions in businesses that are professionalising and consolidating their respective industries with the potential to build platforms.
Water Street Healthcare Partners is dedicated to building market-leading businesses in healthcare. Our team has a history of successful partnerships with middle-market healthcare companies interested in achieving next-level growth. Working closely with leadership teams, we contribute our industry experience and network of resources to advance our shared goals for expansion and value creation. In Europe, our team has supported healthcare businesses with their growth objectives, including expanding their products and services into North America. With more than $6 billion of capital under management, Water Street has completed more than 165 investments and acquisitions, successfully building 45+ companies specializing in life sciences, pharmaceutical services, medical products, diagnostics and healthcare services. To learn more about Water Street’s team and partnership approach, visit waterstreet.com
Strategic Partners
L.E.K. Consulting is a global strategy consultancy with a dedicated Healthcare and Life Sciences practice. We partner with European investors and operators across provider services, medtech, biopharma and digital health to unlock growth and value. Our work spans origination, commercial and vendor due diligence, value-creation planning (pricing, network and capacity, digital), buy-and-build and integration through to exit readiness. We combine sector expertise with proprietary research and on-the-ground European insight to deliver clear, investable answers — fast.
J.P. Morgan is a leader in investment banking, commercial banking, financial transaction processing and asset management. We serve millions of customers, predominantly in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Through continued investments, business initiatives and philanthropic commitments, we aim to help our employees, customers, clients and communities grow and thrive.
McDermott Will & Schulte’s internationally recognized healthcare and life sciences practice addresses the critical legal and business needs of leading industry players. You can turn to us to drive innovative deals and navigate high-stakes disputes, enforcement risks, and complex regulatory issues. Our global team leverages deep market intelligence and decades of experience representing clients across all subsectors, including health systems and other providers, payors, private equity and other investors, major healthcare and life sciences companies, health technology developers, and new market entrants. Serving as a convener, we foster meaningful partnerships and thought leadership through our premier conferences. You also benefit from our exclusive affiliation with healthcare policy and advocacy firm McDermott+, which helps you navigate legislative and regulatory obstacles to maintain competitive advantage. We stand as the only healthcare practice to receive top rankings from Best Law Firms, Chambers, Legal 500, and Law360 (which has named us “Practice Group of the Year for Healthcare” multiple times), while also ranking among the leading life sciences law firms. When you work with us, Always Better isn’t just our goal – it’s your advantage.
The Marwood Group is a healthcare-focused advisory and consulting firm headquartered in New York City with offices in Washington, D.C. and London. With a deep understanding of the influence policy, politics and market dynamics have on reimbursement, regulation, and business performance, Marwood Group supports their client’s investment decisions in assets across Europe and the United States.
Marwood provides investors and operators with policy, regulatory, funding and reimbursement analysis, assessing the risk and opportunities that result from government action on the national or local level. A multilingual European team brings years of relevant healthcare expertise to every engagement.
Compass Carter Osborne delivers exceptional C-suite and executive leadership talent to the investor backed global healthcare and life sciences sectors.
From traditional equity and VC funding through to REITs and infrastructure entrants, CCO is trusted by the investment community to facilitate the placements of elite talent, and have a substantive track record across funding cycles supporting more than 200 leadership hires in the last two years.
CCO is recognised as the most knowledgeable, experienced, and well-networked executive search and advisory services firms in its specialist niche, most recently awarded search firm of the year at the HealthInvestor awards
RSM Ebner Stolz is the leading multidisciplinary mid-market advisory and audit firm in Germany. They work closely with their clients to gain a thorough understanding of their business and provide customized solutions. Their teams of experts help clients manage transformational measures, navigate the complex regulatory landscape and promote sustainable growth. Ebner Stolz joined the RSM network in October 2023.
Healthcare, Pharma and MedTech represent key sectors and the advisory practice in transactions and corporate finance has grown substantially over the past years. They have deep expertise both of the deals environment as well as recent regulatory and commercial market trends with which they navigate clients through a fast-paced and dynamic healthcare and medical industry environment. Working with many of the renowned healthcare private equity investors and players in the market, they support decision-makers throughout the entire investment lifecycle with corporate finance, financial, tax as well as legal and regulatory advisory services. RSM Ebner Stolz consultants follow a multidisciplinary approach by working as “one team” without boundaries to share key knowledge and information between disciplines. This way they cover a multitude of perspectives and add high value to each project.
Howden is a global insurance group, home to over 20,000 talented experts across more than 50 countries.
They provide insurance and risk management solutions across dedicated Private Equity and Healthcare divisions, bringing deep sector expertise and tailored solutions to the complex risk environments you work in. Whatever insurance or risk management needs you’re looking for, Howden can get the right people in the room to create the right solution for you.
Howden’s people are their greatest strength – and largest shareholder group. This unique employee ownership model drives Howden’s culture, fuels their client-first approach, and underpins sustained growth.
Together Howden work to change the insurance narrative – supporting clients while using insurance as a tool to increase resilience for individuals, businesses and communities
Virgin Money, formerly Clydesdale and Yorkshire Bank, has 6.6m retail and business customers across the UK, bringing the best of the Virgin brand to make banking better and enable customers to achieve their financial goals. As part of the Nationwide Building Society since October 2024, Virgin Money is a purpose-led organisation offering a range of straightforward, award-winning products including current accounts, credit cards, savings, investments, mortgages, pensions, loans and more.
The long established and highly regarded business bank offers a broad range of lending solutions and has a focus on specialist sector relationship expertise in key ‘needs’ sectors including health and social care and its related real estate. An inclusive and ambitious culture encourages c.7,000 FTE colleagues to work in a healthy, flexible, digitally-led environment.
Industry Collaborators
Level 20 is a not-for-profit organisation with a mission to increase the number of women working in senior investment roles in European private equity and venture capital to at least 20%. They bring together women working in private equity, enabling them to build their network and find support, mentorship and role models, including from men in the industry. Their work also supports men to understand the barriers women face and be part of the solutions that are driving change. Their sponsor community participates in research and roundtables, sharing feedback and practices, and benefits from Level 20’s resources to support their organisation.
Investors in Healthcare is a Google News approved digital business intelligence platform delivering news, data and analytics for private capital across healthcare, life sciences and pharma in Europe. This knowledge creates actionable insights for investors, corporate leaders and advisors in the sector. The official journal of the European Healthcare Investor Association, it is the leading independent convener of knowledge for the sector using its MAP framework: – Markets (overviews and deep dives including Whitechart PowerPoint slides from leading consulting firms) – Assets (company profiles and Curis Intelligence asset portfolio and deal database including league tables of M&A, equity, debt and real estate deals) – People (moves and Curis Intelligence directory of leading managers, investors and advisors) Combined datasets and seven year, 4,650+ article archive are all searchable using unique ontology – data is curated by cleansing it, structuring it and tagging it so it is AI ready and fully searchable by market, geography and topic.
Associate Members
CMS lawyers work across sectors and borders in more than 40 countries worldwide to deliver advice to you wherever you operate. They see themselves as more than just legal advisers, but as business partners. Their focus is on helping you mitigate risk and benefit from innovation, enabling your business or organisation to thrive.
Bevan Brittan LLP is a market leader in the delivery of legal and regulatory services to the independent health and care market, winning the HealthInvestor “Legal Advisor- Transactional Award” for the last 3 years. Bevan Brittan have an exceptional, award-winning, multi-disciplinary team of 60+ partners and 250 lawyers who passionately and proactively advise health and social care investors and portfolio companies on the full range of operational and transactional matters across all of the major sub-markets of independent health and social care, as well as medtech and life sciences. Last year Bevan Brittan transacted over £30B of businesses/assets, including advising on some of the most important and high-value transactions across elderly and specialist care, children’s services, senior living, private hospitals, diagnostics, med tech, pharmaceuticals, digital and primary care.
Houlihan Lokey is the trusted advisor to more top decision-makers than any other independent global investment bank. They help their clients achieve superior outcomes by providing thoughtful, caring advice while acting with honour and integrity. They are strategic in their approach to growth and are committed to creating lasting value for their shareholders. Houlihan Lokey’s Healthcare Group has earned a reputation for providing superior service and achieving outstanding results in M&A advisory, capital-raising, restructuring, and financial and valuation advisory services. They provide in-depth knowledge, proven transaction experience, and an exceptional level of service to their clients. The team has extensive relationships with public and private strategic and financial sponsors, and the clients they serve span a broad range of sectors.
Latham & Watkins is a global law firm with more than 3,000 lawyers in its offices located in Asia, Europe, the Middle East and the United States. The firm delivers innovative solutions to complex legal and business challenges around the world. Their healthcare and life sciences lawyers advise clients on market-shaping transactions, high-stakes litigation and trials, and sophisticated regulatory matters. The cross-disciplinary healthcare and life sciences private equity team advises the world’s leading private equity firms and brings together strength in fund formation, private equity finance, M&A, and capital markets to deliver seamless and responsive support to private equity clients at every stage of a fund’s lifecycle. The firm has broad experience in advising major private equity players and their portfolio companies on transactions across all relevant sub-sectors within the industry including pharma, medical technology, biotechnology, hospitals and other healthcare services providers and others. Many of their lawyers hold advanced scientific degrees and have served in senior positions as government regulators, C-Suite executives in leading healthcare and life sciences companies, as well as serving as primary outside counsel for key industry associations.
Portolano Cavallo combines in-depth knowledge of the Life Sciences and Healthcare sector, where they are a leading law firm in Italy, with sophisticated Private Equity and Venture Capital expertise, and with full-service capability. Thanks to this, they are uniquely positioned to support Private Equity and Venture Capital funds throughout the investment life cycle and portfolio management. Their expertise encompasses corporate, regulatory and compliance matters, intellectual property, data protection, cybersecurity, competition and consumer law, foreign direct investment (FDI) and more. 60% of their work is cross-border. Expertise in Life Sciences and Healthcare means that they work on all the legal and regulatory issues regarding pharmaceuticals, biotechnologies, medical devices, diagnostics, healthcare, digital health, food supplements, and more. As leaders in Digital, Media and Technology in Italy, Portolano is the go-to firm for complex and cutting-edge matters where technology and Life Sciences intersect. The firm offers innovative solutions to tackle critical business challenges. They are committed to diversity, and place a dedicated focus on sustainability.
Sermo is a fast, frictionless HCP insights and engagement platform connecting healthcare researchers and investors to a global community of over 1 million healthcare professionals across 95+ specialties in 150+ countries.
Leveraging cutting-edge technology and top-tier market research expertise, Sermo delivers robust, real-time insights through 15,000+ surveys and over 755,000 HCP responses annually. Our highly engaged and trusted medical community is dedicated to innovation and advancing patient care, enabling us to provide actionable intelligence that matters.
For over 20 years, Sermo has transformed the expertise and frontline perspectives of healthcare professionals into insights that empower better decisions for life sciences, healthcare partners, and the investment community.
.
